Clinical Trial Update: Sintilimab in FH-deficient Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for sintilimab in FH-deficient renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: West China Hospital | Conditions: Renal Cell Carcinoma, FH-deficient | Phase 2 | Status: UNKNOWN